New asthma shot could help kids breathe easier
NCT ID NCT07671001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The goal is to find better ways to control asthma in young children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- depemokimab (a biologic drug given as an injection)
- What this could lead to
- If successful, depemokimab could become a new add-on treatment option to help control asthma in young children with a specific type of inflammation.
- What could go wrong
- This is a small, early-phase study with only 30 children, so results may not apply broadly. The drug is still experimental, and side effects or lack of effectiveness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?